Gilead Sciences, Inc.

NasdaqGS:GILD Stock Report

Market Cap: US$82.5b

Gilead Sciences Management

Management criteria checks 3/4

Gilead Sciences' CEO is Dan O'Day, appointed in Mar 2019, has a tenure of 5.08 years. total yearly compensation is $22.61M, comprised of 7.7% salary and 92.3% bonuses, including company stock and options. directly owns 0.039% of the company’s shares, worth $32.08M. The average tenure of the management team and the board of directors is 4.2 years and 6.3 years respectively.

Key information

Dan O'Day

Chief executive officer

US$22.6m

Total compensation

CEO salary percentage7.7%
CEO tenure5.1yrs
CEO ownership0.04%
Management average tenure4.2yrs
Board average tenure6.3yrs

Recent management updates

Recent updates

Gilead Sciences: Realizing Financial Projections Is Key

Mar 20

Gilead Sciences' (NASDAQ:GILD) Dividend Will Be Increased To $0.77

Mar 13
Gilead Sciences' (NASDAQ:GILD) Dividend Will Be Increased To $0.77

Gilead's Business Development: The Good, The Bad, And The Spinning Kite Solution

Mar 01

Gilead Sciences (NASDAQ:GILD) Has Announced That It Will Be Increasing Its Dividend To $0.77

Feb 28
Gilead Sciences (NASDAQ:GILD) Has Announced That It Will Be Increasing Its Dividend To $0.77

We Think Gilead Sciences' (NASDAQ:GILD) Solid Earnings Are Understated

Feb 15
We Think Gilead Sciences' (NASDAQ:GILD) Solid Earnings Are Understated

Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.77

Feb 13
Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.77

Gilead Sciences: Cheap For A Reason

Feb 10

Gilead Sciences: The Sky Is Not Falling

Feb 01

Does Gilead Sciences (NASDAQ:GILD) Deserve A Spot On Your Watchlist?

Jan 15
Does Gilead Sciences (NASDAQ:GILD) Deserve A Spot On Your Watchlist?

What Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E Is Not Telling You

Dec 25
What Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E Is Not Telling You

These 4 Measures Indicate That Gilead Sciences (NASDAQ:GILD) Is Using Debt Reasonably Well

Nov 17
These 4 Measures Indicate That Gilead Sciences (NASDAQ:GILD) Is Using Debt Reasonably Well

Does Gilead Sciences (NASDAQ:GILD) Deserve A Spot On Your Watchlist?

Oct 10
Does Gilead Sciences (NASDAQ:GILD) Deserve A Spot On Your Watchlist?

We Think Gilead Sciences (NASDAQ:GILD) Can Stay On Top Of Its Debt

Aug 11
We Think Gilead Sciences (NASDAQ:GILD) Can Stay On Top Of Its Debt

Here's Why Gilead Sciences (NASDAQ:GILD) Has Caught The Eye Of Investors

Jul 04
Here's Why Gilead Sciences (NASDAQ:GILD) Has Caught The Eye Of Investors

CEO Compensation Analysis

How has Dan O'Day's remuneration changed compared to Gilead Sciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023US$23mUS$2m

US$6b

Sep 30 2023n/an/a

US$6b

Jun 30 2023n/an/a

US$5b

Mar 31 2023n/an/a

US$6b

Dec 31 2022US$22mUS$2m

US$5b

Sep 30 2022n/an/a

US$3b

Jun 30 2022n/an/a

US$4b

Mar 31 2022n/an/a

US$5b

Dec 31 2021US$19mUS$2m

US$6b

Sep 30 2021n/an/a

US$7b

Jun 30 2021n/an/a

US$5b

Mar 31 2021n/an/a

US$301m

Dec 31 2020US$19mUS$2m

US$123m

Sep 30 2020n/an/a

US$1b

Jun 30 2020n/an/a

-US$257m

Mar 31 2020n/an/a

US$5b

Dec 31 2019US$29mUS$1m

US$5b

Compensation vs Market: Dan's total compensation ($USD22.61M) is above average for companies of similar size in the US market ($USD13.41M).

Compensation vs Earnings: Dan's compensation has been consistent with company performance over the past year.


CEO

Dan O'Day (59 yo)

5.1yrs

Tenure

US$22,607,690

Compensation

Mr. Daniel P. O'Day, also known as Dan, served as Non-Executive Non-Independent Director for Galapagos NV since October 22, 2019 until March 26, 2024. He served as Member of Supervisory Board at Galapagos...


Leadership Team

NamePositionTenureCompensationOwnership
Daniel P. O'Day
Chairman & CEO5.1yrsUS$22.61m0.039%
$ 32.1m
Andrew Dickinson
Chief Financial Officer4.4yrsUS$8.11m0.011%
$ 8.9m
Deborah Telman
Executive VP of Corporate Affairs1.7yrsUS$5.27m0.0011%
$ 907.5k
Johanna Mercier
Chief Commercial Officer4.8yrsUS$8.59m0.0095%
$ 7.8m
Merdad Parsey
Chief Medical Officer4.4yrsUS$8.39m0.0077%
$ 6.4m
Sandra Patterson
Senior VP1.1yrsno data0.0026%
$ 2.2m
Jacquie Ross
Vice President of Investor Relations3.3yrsno datano data
Jyoti Mehra
Executive Vice President of Human Resources4.7yrsno datano data
Linda Higgins
Senior Vice President of Research4.2yrsno datano data
Rudolf Ertl
Senior Vice President of Commercial Operations of Australiano datano datano data
Flavius Martin
Executive Vice President of Research3yrsno datano data
William Grossman
Senior Vice President & Therapeutic Area Head of Gilead Oncology2.8yrsno datano data

4.2yrs

Average Tenure

57yo

Average Age

Experienced Management: GILD's management team is considered experienced (4.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Daniel P. O'Day
Chairman & CEO5.1yrsUS$22.61m0.039%
$ 32.1m
Anthony Welters
Independent Director3.5yrsUS$444.92k0.00064%
$ 528.0k
Paul Berg
Member of Scientific Advisory Boardno dataUS$16.00kno data
Jacqueline Barton
Independent Director6.3yrsUS$429.92k0.0018%
$ 1.5m
Eugene Schiff
Member of the Scientific Advisory Boardno datano datano data
Robert Schooley
Member of the Scientific Advisory Boardno datano datano data
John Mellors
Member of the Scientific Advisory Boardno datano datano data
Francis Chisari
Member of the Scientific Advisory Boardno datano datano data
Paul Klotman
Member of the Scientific Advisory Boardno datano datano data
Kevin Lofton
Lead Independent Director14.8yrsUS$507.44k0.0074%
$ 6.1m
Kelly Kramer
Independent Director7.7yrsUS$434.92k0.00011%
$ 90.7k
Joel Huff
Chairperson of Scientific Advisory Boardno datano datano data

6.3yrs

Average Tenure

68yo

Average Age

Experienced Board: GILD's board of directors are considered experienced (6.3 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.